tbuckley/cabot-search huggingface dataset:
A Phase II Trial of Bevacizumab with Capecitabine in Progressive, Metastatic Well-Differentiated Digestive Endocrine Tumors (Better Study)
Authors: T.A. Walter, E. Baudin, J.E. Kurtz, P. Ruszniewski, L. Bengrine-Lefevre, G. Cadiot, S. Dominguez-Tinajero, S. Kraemer, M.P. Ducreux, E. Mitry
Journal: Annals of Oncology (2012)
S-1 Monotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck after Progression on Platinum-Based Chemotherapy
Authors: T. Yokota, Y. Onozawa, N. Boku, S. Hamauchi, T. Tsushima, H. Taniguchi, A. Todaka, N. Machida, K. Yamazaki, A. Fukutomi, H. Yasui
Journal: Annals of Oncology (2012)
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
Authors: James R. Berenson, Jennifer To, Tanya M. Spektor, Daisy Martinez, Carley Turner, Armando Sanchez, Matthew Ghermezi, Benjamin M. Eades, Regina A. Swift, Gary Schwartz, Shahrooz Eshaghian, Laura Stampleman, Robert A. Moss, Stephen Lim, Robert Vescio
Journal: Clinical Cancer Research (2020)

Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity to lenalidomide. Therefore, a phase I trial was conducted to determine the safety and efficacy of ruxolitinib with lenalidomide and methylprednisolone for patients with relapsed/refractory multiple myeloma (RRMM) who had been treated with lenalidomide/steroids and a proteasome inhibitor and showed progressive disease at study entry.A traditional 3+3 dose escalation design was used to enroll subjects in four cohorts with planned total enrollment of 28 patients. Subjects received ruxolitinib twice daily, lenalidomide daily on days 1-21 of a 28-day cycle, and methylprednisolone orally every other day. Primary endpoints were safety, clinical benefit rate (CBR), and overall response rate (ORR).Twenty-eight patients were enrolled. The median age was 67 years and received a median of six prior treatments including lenalidomide and steroids to which 93% were refractory. No dose-limiting toxicities occurred. The CBR and ORR were 46% and 38%, respectively. All 12 responding patients were refractory to lenalidomide. Grade 3 or grade 4 adverse events (AE) included anemia (18%), thrombocytopenia (14%), and lymphopenia (14%). Most common serious AEs included sepsis (11%) and pneumonia (11%).This phase I trial demonstrates that a JAK inhibitor, ruxolitinib, can overcome refractoriness to lenalidomide and steroids for patients with RRMM. These results represent a promising novel therapeutic approach for treating multiple myeloma (ClinicalTrials.gov number, NCT03110822).
Lung Adenocarcinoma with Discordant Results for ALK Based on Immunohistochemistry (IHC) Versus Fluorescence in SITU Hybridization (FISH): A Case Report
Authors: C. Kondo, J. Park, J. Shimizu, Y. Horio, K. Yoshida, Y. Yatabe, T. Hida
Journal: Annals of Oncology (2012)
Significantly Superior Outcome After Neoadjuvant Chemotherapy With Docetaxel, Anthracycline and Cyclophosphomide Versus Docetaxel Plus Cyclophosphomide: Results From the Natt Trial in Triple Negative or HER2 Positive Breast Cancer
Authors: X. Chen, G. Ye, C. Zhang, X. Li, K. Shen
Journal: Annals of Oncology (2012)
Sequential versus concurrent treatment of breast cancer cell-lines using the farnesyl transferase inhibitor, manumycin A, and mebendazole
Authors: Rania M. Dababneh, Diana S-L. Chow, S-C. J. Yeung
Journal: Cancer Research (2006)

2137  Objective: To evaluate the potential synergistic effect of the combination compared to single drug treatment using Manumycin A (MA) and Mebendazole (Mbz). And to determine the significance of sequential over concurrent treatment using these two drugs. Methods: Three breast cancer cell-lines (MDA-MB-231, MCF-7 and MCF-7 Her-18) were grown in DMEM medium in 96-well microplates (at 5,000 cells in 100 μL culture medium). Drug stock solutions were separately prepared in sterile DMSO, and further diluted with 0.1% DMSO containing culture medium to achieve the IC25 concentrations of MA and Mbz previously determined for each cell-line. For concurrent treatment, MA was combined with Mbz and incubated at 37oC for 48 hours. For sequential treatments, either MA or Mbz was incubated at 37oC for 24 hours, then the cells were washed with PBS, MA treated cells received Mbz, while the Mbz treated cells received MA. Microplates were incubated for an additional 24 hours. Cell viability was determined using XTT assay, n= 16 for each treatment from 2-3 independent runs. Results: For treatment with MA as a single agent the percent viabilities (%+SD) were 63.3+10.7 for MDA-MB-231, 65.7+3.4 for MCF-7, and 67.9+ 10.2 for MCF-7 Her-18. Percent viabilities for Mbz as a single agent were 91.9+16.5, 76.7+3.7, and 93.3+6.2 for MDA-MB-231, MCF-7, and MCF-7 Her-18, respectively. For concurrent treatment the percent viabilities (%+SD) were 60.0+7.6 for MDA-MB-231, 54.5+4.2 for MCF-7, and 61.1+ 26.0 for MCF-7 Her-18. The concurrent treatment did not enhance the effect of MA using a single agent, except in MCF-7 that the percent viability further decreased from 65.7 to 54.5%. For sequential treatment with MA first the percent viabilities were: 49.9+9.8, 27.0+4.8, and 20.0+ 9.6 for MDA-MB-231, MCF-7, and MCF-7 Her-18 respectively. While the percent viabilities with Mbz-first treatment were: 48.3+28, 47.45+8.26, and 32.12+ 9.53 for MDA-MB-231, MCF-7, and MCF-7 Her-18 respectively. Sequential treatments significantly enhanced the cytotoxicity of individual agents. In all three cell lines, sequential treatments with the two protocols exerted enhancements. The MA-first sequence was more effective than Mbz-first. Greater enhancements were observed in MCF-7 and MCF-7 Her-18 than in MB-231for MA-first sequential treatment. The MCF-7 Her-18 is more susceptible than the other two lines when Mbz was used first. Conclusion: In all three cell lines, Sequential treatment was superior to concurrent treatment. MA first treatment was more effective compared to Mbz first in MCF-7 and MCF-7 Her18 cells. While the sequence did not have an effect in MDA-231 cells.
Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease
Authors: Corey E. Ventetuolo, Jason M. Aliotta, Julie Braza, Havovi Chichger, Mark Dooner, Donald McGuirl, Christopher J. Mullin, Julie Newton, Mandy Pereira, Amy Princiotto, Peter J. Quesenberry, Thomas Walsh, Mary Whittenhall, James R. Klinger, Elizabeth O. Harrington
Journal: European Respiratory Journal (2020)

Endothelial dysfunction is a hallmark of pulmonary arterial hypertension (PAH) but there are no established methods to study pulmonary artery endothelial cells (PAECs) from living patients. We sought to culture PAECs from pulmonary artery catheter (PAC) balloons used during right-heart catheterisation (RHC) to characterise successful culture attempts and to describe PAEC behaviour.PAECs were grown in primary culture to confluence and endothelial cell phenotype was confirmed. Standard assays for apoptosis, migration and tube formation were performed between passages three to eight. We collected 49 PAC tips from 45 subjects with successful PAEC culture from 19 balloons (39%).There were no differences in subject demographic details or RHC procedural details in successful versus unsuccessful attempts. However, for subjects who met haemodynamic criteria for PAH, there was a higher but nonsignificant (p=0.10) proportion amongst successful attempts (10 out of 19, 53%) versus unsuccessful attempts (nine out of 30, 30%). A successful culture was more likely in subjects with a lower cardiac index (p=0.03) and higher pulmonary vascular resistance (p=0.04). PAECs from a subject with idiopathic PAH were apoptosis resistant compared to commercial PAECs (p=0.04) and had reduced migration compared to PAECs from a subject with portopulmonary hypertension with high cardiac output (p=0.01). PAECs from a subject with HIV-associated PAH formed fewer (p=0.01) and shorter (p=0.02) vessel networks compared to commercial PAECs.Sustained culture and characterisation of PAECs from RHC balloons is feasible, especially in PAH with high haemodynamic burden. This technique may provide insight into endothelial dysfunction during PAH pathogenesis.
Somatic Kras Mutations and Resistance to EGFR-Targeted Therapies: Is Kras Ready to Include as a Reflex Test With EGFR in NSCLC? An Evidence Synthesis Based Approach
Authors: S. Murray, F. Siannis, D. Bafaloukos, P. Kosmidis, H. Linardou
Journal: Annals of Oncology (2012)
Oral S-1 and Carboplatin Plus Bevacizumab with Maintenance S-1 and Bevacizumab for Chemo-Naïve Patients with Non-Squamous Non-Small-Cell Lung Cancer
Authors: Y. Urata, I. Okamoto, Y. Hattori, K. Okuno, T. Shimada, M. Takeda, T. Kurata, H. Kaneda, M Miyazaki, M. Terashima, K. Tanaka, S Morita, K. Nakagawa, S. Negoro, M. Satouchi
Journal: Annals of Oncology (2012)
Pten and Advanced Colorectal Cancer (CRC): Analysis from the Phase III Agitg Max Trial of Capecitabine Alone or in Combination with Bevacizumab +/- Mitomycin C
Authors: T. Price, J. Hardingham, C. Lee, A. Townsend, J. Wrin, K. Wilson, A. Weickhardt, R.J. Simes, C. Munroe, N. Tebbutt
Journal: Annals of Oncology (2012)
Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort
Authors: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, Patricia Landis, Katarzyna J. Macura, Demetrios N. Simopoulos, H. Ballentine Carter, Michael A. Gorin
Journal: European Urology (2020)
Efficacy of Platinum Plus Gemcitabine (G) in Platinum-Resistant (R) Compared to Platinum-Sensitive (S) Ovarian Cancer: the Royal Marsden Experience
Authors: A. George, N. Tunariu, N. Wilkinson, S. Gupta, M.E. Gore, S.B. Kaye, S. Banerjee
Journal: Annals of Oncology (2012)
Dialogic Praxis — A 16-Year-Old Boy with Anxiety in Southern Brazil
Authors: Dominique P. Béhague, Raphael G. Frankfurter, Helena Hansen, Cesar G. Victora
Journal: New England Journal of Medicine (2020)

Interview with Dr. Dominique Béhague on therapeutic strategies that rely on bidirectional critical analysis and learning. (14:51)Download Sent to a psychiatrist because of aggressive behavior and social withdrawal, a Brazilian teenager is empowered by the doctor's dialogic approach and addresses his anger and anxiety by working on the school council to change the conditions that led to his symptoms.
A Phase 1B Study to Evaluate the Safety and Pharmacology of the Dual PI3K-MTOR Inhibitor GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab (BEV) in Patients with Advanced Solid Tumors
Authors: L.S. Rosen, J. Goldman, S. Stewart, J.M. Hubbard, M. Roos, W. Lin, G. Shankar, J. Capdevila, E. Freas, S. Leong
Journal: Annals of Oncology (2012)
Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations
Authors: Hanif Esmail, Frank Cobelens, Delia Goletti
Journal: European Respiratory Journal (2020)

<b>The new experimental tools to detect incipient tuberculosis (TB) in those with latent TB infection can be clinically relevant for achieving global TB control. In this manuscript, how such tests fit may into future TB management is discussed.</b>http://bit.ly/35WiozD
Stimulation of Erythropoiesis by Thalidomide in Multiple Myeloma Patients: Its Influence on FasL, TRAIL and Their Receptors on Erythroblasts and Plasma Cells.
Authors: Norbert Grzasko, Marek Hus, Maria Soroka-Wojtaszko, Piotr Klimek, Aneta Goracy, Anna Dmoszynska
Journal: Blood (2005)
Down-Regulation of γ-Glutamyl Hydrolase Gene Expression in Tumor Tissues is Associated with Response to Oral Uracil and Tegafur/Leucovorin Chemotherapy in Patients with Colorectal Cancer
Authors: S. Sadahiro, T. Suzuki, A. Tanaka, K. Okada, A. Kamijo, H. Nagase, J. Uchida
Journal: Annals of Oncology (2012)
Quality of Life and Symptoms in Breast Cancer Patients Undergoing Conventional Chemotherapy
Authors: T.P. Nikitina, K.A. Kurbatova, I.V. Rykov, N.A. Polyakova, L.V. Kindyanova, A.M. Yermachenkova, D.A. Fedorenko, T.I. Ionova
Journal: Annals of Oncology (2012)
High Expression of BCL-2 Predicts Poor Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Chop-Based Chemotherapy
Authors: H.W. Lee, J.-H. Choi, M.S. Ahn, S.Y. Kang, S.H. Jeong, J.S. Park, J.H. Han, J.H. Kim
Journal: Annals of Oncology (2012)
P-0136 10 Cases of Non-Hodgkin's Lymphoma that Caused Gastrointestinal Perforation - Experience in our Department
Authors: Kazuhiko Natori, Susumu Ishihara, Daisuke Nagase, Akiko Shibuya, Yukitoshi Toyoda, Yoshinori Fujimoto, Yasunobu Kuraishi, Tetsuo Nemoto, Kazutoshi Shibuya, Haruka Izumi
Journal: Annals of Oncology (2012)
Molecular Profiling of High-Risk Localized Prostate Cancer (HRLPC) Treated With Docetaxel (D) and Complete Androgen Blockade (CAB) Prior To Radical Prostatectomy
Authors: M. Marín-Aguilera, A. Font, E. Gallardo, A. Alcaraz, V. Pereira, M.J. Ribal, J. Areal, N. Hannaoui, P. Gascon, B. Mellado
Journal: Annals of Oncology (2012)
The Caregivers Perspective On The End-of-Life Phase of Glioblastoma Patients
Authors: B. Flechl, M. Ackerl, C. Sax, S. Oberndorfer, B. Calabek, E. Sizoo, J. Reijneveld, R. Crevenna, M. Preusser, C. Marosi
Journal: Annals of Oncology (2012)
Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of Mek Inhibitor, RO4987655, in Japanese Patients with Advanced Solid Tumors
Authors: S. Nakamichi, H. Nokihara, N. Yamamoto, Y. Tamura, K. Honda, H. Wakui, Y. Yamada, N. Yamazaki, S. Suzuki, T. Tamura
Journal: Annals of Oncology (2012)
Characteristics of 982 Lung Cancer Patients in Serbia According to the WHO/IASLC Classification of Lung Cancers and Subsequent Treatment – Avatar Epidemiology Study
Authors: D. Jovanovic, N. Secen, Z. Murtezani, M. Rancic, V. Kacar-Kukric, M. Velinovic, A. Tepavac, E. Budisin, Z.G. Andric, N. Vukobradovic Djoric
Journal: Annals of Oncology (2012)
Utility of a Novel Quantitative EGFR Mutated Protein Analysis Using Aqua System for EGFR-TKI Treatment in Non-Small Cell Lung Cancer Patients
Authors: K. Goto, G. Ishii, K. Fujimoto-Ouchi, M. Shirane, H. Ohmatsu, S. Niho, K. Yoh, S. Umemura, K. Nagai, Y. Ohe
Journal: Annals of Oncology (2012)
Final Report on Phase 1 Clinical Trial of Oral Pparгagonist Efatutazone (CS-7017) in Japanese Patients with Metastatic Solid Tumors
Authors: Y. Onozawa, H. Murakami, A. Ono, T. Tushima, T. Takahashi, K. Yamazaki, Y. Nakamura, T. Jiko, N. Boku, N. Yamamoto
Journal: Annals of Oncology (2012)
Impact of the Interval Between Surgery and Adjuvant MFOLFOX6 on Survival of Colon Cancer Patients
Authors: J. Godinho Bexiga, F. Carneiro, D.S. Marques, N. Sousa, C. Faustino, A. Raimundo, M. Machado, P. Ferreira, M. Fragoso
Journal: Annals of Oncology (2012)
Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, August 2019–January 2020
Authors: Vikram P. Krishnasamy, Benjamin D. Hallowell, Jean Y. Ko, Amy Board, Kathleen P. Hartnett, Phillip P. Salvatore, Melissa Danielson, Aaron Kite-Powell, Evelyn Twentyman, Lindsay Kim, Alissa Cyrus, Megan Wallace, Paul Melstrom, Brittani Haag, Brian A. King, Peter Briss, Christopher M. Jones, Lori A. Pollack, Sascha Ellington, Amena Abbas, Adebola Adebayo, Sukhshant Atti, Tegan Boehmer, Elizabeth Carter, Gyan Chandra, Lindsay Eckhaus, Janet Hamilton, Mia Israel, Zheng Li, Caitlin Loretan, Ruth Lynfield, Nisha Nataraj, Mary Pomeroy, Caroline Schrodt, Herschel Smith, Kimberly Thomas, Angela Werner
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Since August 2019, CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders have been investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). This report updates patient demographic characteristics, self-reported substance use, and hospitalization dates for EVALI patients reported to CDC by states, as well as the distribution of emergency department (ED) visits related to e-cigarette, or vaping, products analyzed through the National Syndromic Surveillance Program (NSSP). As of January 14, 2020, a total of 2,668 hospitalized EVALI cases had been reported to CDC. Median patient age was 24 years, and 66% were male. Overall, 82% of EVALI patients reported using any tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product (including 33% with exclusive THC-containing product use), and 57% of EVALI patients reported using any nicotine-containing product (including 14% with exclusive nicotine-containing product use). Syndromic surveillance indicates that ED visits related to e-cigarette, or vaping, products continue to decline after sharply increasing in August 2019 and peaking in September 2019. Clinicians and public health practitioners should remain vigilant for new EVALI cases. CDC recommends that persons not use THC-containing e-cigarette, or vaping, products, especially those acquired from informal sources such as friends, family members, or from in-person or online dealers. Vitamin E acetate is strongly linked to the EVALI outbreak and should not be added to any e-cigarette, or vaping, products (2). However, evidence is not sufficient to rule out the contribution of other chemicals of concern, including chemicals in either THC- or non-THC-containing products, in some reported EVALI cases.
Association between Bevacizumab-Related Hypertension and VEGF Gene Polymorphisms in Japanese Colorectal Cancer Patients
Authors: S. Morita, M. Inada, T. Shibata, T. Oguri, T. Shimokata, M. Sugishita, A. Mitsuma, K. Uehara, G. Nakayama, Y. Ando
Journal: Annals of Oncology (2012)
Acute Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) in Patients (PTS) with Lung Cancer Under Various Treatments
Authors: H. Asahina, S. Oizumi, Y. Fujita, K. Takamura, T. Kojima, T. Harada, Y. Kawai, H. Dosaka-Akita, H. Isobe, M. Nishimura
Journal: Annals of Oncology (2012)
Does Gefitinib Re-challenge or Treatment Beyond Progression (TBP) Prolong Survival of NSCLC Patients? - Real World Evidence from Gefitinib Treatment Responders
Authors: Y. Namba, F. Imamura, S. Morita, M. Mori, K. Komuta, T. Kijima, Y. Nakazawa, S. Yokota, S. Yamamoto, A. Kumanogoh
Journal: Annals of Oncology (2012)
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
Authors: Aneta Schieferdecker, Sebastian Hörber, Monika Ums, Britta Besemer, Carsten Bokemeyer, Andreas Peter, Katja Weisel
Journal: Blood Cancer Journal (2020)

The measurement of serum-free light chains (FLC) is standard of care in the diagnosis and management of multiple myeloma (MM). The revised international myeloma working group (IMWG) implemented the involved FLC/noninvolved FLC (iFLC/niFLC) ratio as a biomarker for MM requiring treatment. Recently, a new definition of high-risk smoldering MM (SMM) including iFLC/niFLC ratio was published. These recommendations were solely based on a single assay method (Freelite assay). Today, two additional assays, N Latex FLC and ELISA-based Sebia FLC, are available. Here, we report on a single-center-study comparing results of all three different assays for FLC correlation and its potential implications for diagnostic and clinical use. In total, 187 samples from 47 MM patients were examined, and determination of FLC was performed. Comparison analyses showed similar FLC results for Sebia FLC and N Latex FLC assay with markedly lower absolute values for κ/λ ratio compared with Freelite. Values of λ FLC exhibited high variability. The ratio of iFLC/niFLC showed significant discrepancies among these assays. Our data demonstrate that the three available assays may result in markedly discrepant results, and should not be used interchangeably to monitor patients. Furthermore, modifications of the assay-specific diagnostic (iFLC/niFLC) thresholds for SMM and MM are recommended.
First Report of Long-Term Responders to First-Line Bevacizumab (BEV) Combined With Chemotherapy in Two Independent Cohorts of HER2-Neg Metastatic Breast Cancer Patients (PTS) With Hormone Receptor –Positive (HR+) and Triple-Negative (TN) Tumors
Authors: M. Saghatchian, C. Levy, C.B. Villanueva, J. Fleury, V. Diéras, A. Mercier-Blas, H. Simon, C. Le Maignan, N. Mesnard, E. Antoine
Journal: Annals of Oncology (2012)
Telomerase Contributes To Repair Of DNA Breaks In Myeloma Cells By Incorporating “TTAGGG” Sequences Within Genome: Biological and Translational Significance
Authors: Jagannath Pal, Jie Ding, Subodh Kumar, Zachary Hunter, Teresa Calimeri, Jianhong Lin, Maria Gkotzamanidou, Giovanni Parmigiani, Steven Treon, Masood Shammas, Nikhil Munshi
Journal: Blood (2013)
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Aaron T. Scott, Michelle Weitz, Patrick J. Breheny, Po Hien Ear, Benjamin Darbro, Bart J. Brown, Terry A. Braun, Guiying Li, Shaikamjad Umesalma, Courtney A. Kaemmer, Chandra K. Maharjan, Dawn E. Quelle, Andrew M. Bellizzi, Chandrikha Chandrasekharan, Joseph S. Dillon, Thomas M. O'Dorisio, James R. Howe
Journal: Clinical Cancer Research (2020)

Pancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past decades, most patients will die of metastatic disease. New systemic therapies are needed.
P-0025 Modified Folfiri (mFolfiri) as Second Line Chemotherapy in Advanced Gastric Cancer (AGC)
Authors: Arslane Rahal, Valerie Boige, Malka David, Chahinez Rahal, Pascal Burtin, Isabelle Sinapi, Dominique Elias, Diane Goere, Benjamin Lacas, Michel Ducreux
Journal: Annals of Oncology (2012)
Parathyroid hormone–dependent bone formation requires butyrate production by intestinal microbiota
Authors: Jau-Yi Li, Mingcan Yu, Subhashis Pal, Abdul Malik Tyagi, Hamid Dar, Jonathan Adams, M. Neale Weitzmann, Rheinallt M. Jones, Roberto Pacifici
Journal: Journal of Clinical Investigation (2020)

Parathyroid hormone (PTH) is a critical regulator of skeletal development that promotes both bone formation and bone resorption. Using microbiota depletion by wide-spectrum antibiotics and germ-free (GF) female mice, we showed that the microbiota was required for PTH to stimulate bone formation and increase bone mass. Microbiota depletion lowered butyrate levels, a metabolite responsible for gut-bone communication, while reestablishment of physiologic levels of butyrate restored PTH-induced anabolism. The permissive activity of butyrate was mediated by GPR43 signaling in dendritic cells and by GPR43-independent signaling in T cells. Butyrate was required for PTH to increase the number of bone marrow (BM) regulatory T cells (Tregs). Tregs stimulated production of the osteogenic Wnt ligand Wnt10b by BM CD8+ T cells, which activated Wnt-dependent bone formation. Together, these data highlight the role that butyrate produced by gut luminal microbiota plays in triggering regulatory pathways, which are critical for the anabolic action of PTH in bone.